Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
Date:5/9/2011

same period in 2010 of $10.1 million, or $0.54 per share.  The increase in net loss per share for the three months ended March 31, 2011 compared to the same period in 2010 was a result of the increase in net loss, partially offset by an increase in weighted-average shares outstanding in 2011 as a result of our April 2010 and February 2011 public offerings of common stock.ARDEA BIOSCIENCES, INC.Condensed Consolidated Statements of Operations(in thousands, except per share amounts)Three Months Ended

March 31,

(Unaudited)20112010Revenues: License fees

$

1,077$

2,426 Sponsored research90— Reimbursable research and development costs603847Total revenues1,7703,273Operating expenses: Research and development12,71510,251 General and administrative4,2492,926Total operating expenses16,96413,177Loss from operations(15,194)(9,904)Other income (expense): Interest income10769 Interest expense(134)(261) Other income, net313Total other income (expense)(24)(179)Net loss

$

(15,218)$

(10,083)Basic and diluted net loss per share

$

(0.59)$

(0.54)Shares used in computing basic and diluted net loss per share 25,78218,559Condensed Consolidated Balance Sheet Data(in thousands)March 31,

2011

(Unaudited)December 31,

2010Cash, cash equivalents and short-term investments

$

156,805$

80,612Total assets

$

162,169$

100,454Total stockholders' equity

$

143,368$

77,123About Ardea Biosciences, Inc.Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad (RDEA594), our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter.  We have completed Phase 2b clinical studies of lesinurad and continue t
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
3. Ardea Biosciences Prices Public Offering of Common Stock
4. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
10. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
11. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)... Sterlitech is proud to debut its multi-line, ... 2015 AMTA Membrane Technology Conference in Orlando. This ... of engineering and customer feedback, which has resulted in ... applications across an array of disciplines. It is ... needs of researchers and engineers alike and is ideal ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... today published analyses of its second-generation map of ... markers than the initial version unveiled in 2005. ... consortium describes how the higher resolution map offers ... common diseases, explore the structure of human genetic ...
... FRANCISCO, Calif., Oct. 17 Monogram,Biosciences, Inc., (Nasdaq: ... on Wednesday, October 24, 2007 at 4:30 p.m. (Eastern ... will be hosted by Mr.,William D. Young, Chairman and ... teleconference, please call (877) 548-7912,or (719) 325-4878 for international ...
... ARNA ) today reported financial results for the ... the third quarter of 2007 were $5.0 million, compared,to ... revenues in the first,nine months of 2007 were $14.8 ... of 2006. Revenues in the first nine months of ...
Cached Biology Technology:Consortium publishes Phase II map of human genetic variation 2Consortium publishes Phase II map of human genetic variation 3Consortium publishes Phase II map of human genetic variation 4Consortium publishes Phase II map of human genetic variation 5Consortium publishes Phase II map of human genetic variation 6Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to ... biometrics technology is to ensure that an individual is who ... technology may make use of a person,s unique physical characteristics, ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... Robert Burns compared his love to a red, red rose, ... rather than being topped by a lovely, fragrant bloom, a ... crowned by a homely second root. , Researchers at the ... plant Arabidopsis thaliana rather than the elegant rose recently determined ...
... University at Buffalo have received a $2.5 million five-year ... dysfunction called "hibernating myocardium" that can cause disabling heart ... a condition in which myocytes (cells in the heart's ... that receive reduced blood flow over an extended period ...
... University of Florida scientists conducting experiments with mice have ... of cells in the eye essential for healthy vision. ... cell layer vital for eyesight called the retinal pigment ... writing in a recent issue of Investigative Ophthalmology & ...
Cached Biology News:Salk scientists get to the root of plant cell fate 2Salk scientists get to the root of plant cell fate 3Reversing 'hibernating' heart muscle focus of UB researchers 2Bone marrow may restore cells lost in vision diseases 2Bone marrow may restore cells lost in vision diseases 3
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: